2.5905

3.76% -0.0995

Iovance Biotherapeutics Inc (IOVA)

Overview News Price History Option Chain Financials Why IOVA Down? Discussions Forecast Stock Split

Iovance Biotherapeutics Inc stock is traded at $2.5905, with a volume of 3.84M. It is down -3.76% in the last 24 hours and down -8.20% over the past month. Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Previous Close:

$2.69

Open:

$2.67

24h Volume:

3.84M

Relative Volume:

0.27

Market Cap:

$1.03B

Revenue:

$241.53M

Net Income/Loss:

$-389.92M

P/E Ratio:

-2.1061

EPS:

-1.23

Net Cash Flow:

$-323.54M

1W Performance:

+9.70%

1M Performance:

-8.20%

6M Performance:

-34.79%

1Y Performance:

-58.18%

1-Day Range:

$2.58

$2.69

1-Week Range:

$2.24

$2.72

52-Week Range:

$1.6385

$6.50

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Name

Iovance Biotherapeutics Inc

Sector

Healthcare (1119)

Industry

Biotechnology (625)

Phone

(650) 260-7120

Address

825 INDUSTRIAL ROAD, SAN CARLOS

Employee

838

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

IOVA's Discussions on Twitter

Compare IOVA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IOVA Iovance Biotherapeutics Inc	2.595	1.07B	241.53M	-389.92M	-323.54M	-1.23
VRTX Vertex Pharmaceuticals Inc	463.83	118.58B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	749.34	79.40B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	811.57	51.18B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	360.88	48.88B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	339.19	37.49B	4.98B	69.59M	525.67M	0.5197

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-15-25	Downgrade	Goldman	Neutral → Sell
May-16-25	Downgrade	UBS	Buy → Neutral
May-12-25	Downgrade	Truist	Buy → Hold
May-09-25	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
Oct-24-24	Initiated	UBS	Buy
Jul-29-24	Downgrade	Piper Sandler	Overweight → Neutral
Nov-20-23	Initiated	Goldman	Buy
Sep-18-23	Reiterated	Barclays	Overweight
May-30-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Mar-27-23	Resumed	Wells Fargo	Equal Weight
Jan-27-23	Upgrade	Piper Sandler	Neutral → Overweight
Dec-09-22	Downgrade	Goldman	Buy → Neutral
Oct-31-22	Initiated	Guggenheim	Neutral
Aug-18-22	Resumed	Wells Fargo	Equal Weight
Jan-28-22	Upgrade	Stifel	Hold → Buy
Dec-07-21	Resumed	Cowen	Outperform
Jun-10-21	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
May-20-21	Downgrade	Piper Sandler	Overweight → Neutral
May-19-21	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
May-19-21	Downgrade	Stifel	Buy → Hold
May-03-21	Initiated	Truist	Buy
Apr-16-21	Initiated	Goldman	Buy
Mar-08-21	Upgrade	H.C. Wainwright	Neutral → Buy
Dec-15-20	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-06-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-22-20	Initiated	Mizuho	Buy
Mar-04-20	Initiated	Barclays	Overweight
Feb-26-20	Reiterated	H.C. Wainwright	Buy
Feb-26-20	Reiterated	Oppenheimer	Outperform
Dec-18-19	Initiated	JMP Securities	Mkt Outperform
Oct-01-19	Initiated	Stifel	Buy
Apr-29-19	Initiated	Piper Jaffray	Overweight
Feb-28-19	Reiterated	Chardan Capital Markets	Buy
Feb-07-19	Initiated	Robert W. Baird	Outperform
Dec-31-18	Resumed	B. Riley FBR	Buy
Jul-06-18	Reiterated	Chardan Capital Markets	Buy
Apr-10-18	Upgrade	B. Riley FBR, Inc.	Neutral → Buy
Mar-13-18	Reiterated	B. Riley FBR, Inc.	Neutral
Feb-23-18	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
Jan-25-18	Reiterated	H.C. Wainwright	Buy
Nov-01-17	Reiterated	B. Riley FBR, Inc.	Buy

View All

Iovance Biotherapeutics Inc Stock (IOVA) Latest News

Jan 20, 2026

Advanced Melanoma Pipeline Expands With 60+ Investigational Therapies and 55+ Active Developers, Reports DelveInsight - Barchart.com

Jan 20, 2026

Advanced Melanoma Pipeline Expands With 60+ Investigational - openPR.com

Jan 20, 2026

Jan 18, 2026

Bull Run: Is Iovance Biotherapeutics Inc showing insider buyingEarnings Performance Report & Accurate Technical Buy Alerts - baoquankhu1.vn

Jan 18, 2026

Assessing Iovance Biotherapeutics (IOVA) Valuation After Clinical Trial Progress And New FDA Designations - Sahm

Jan 18, 2026

What drives Iovance Biotherapeutics Incs stock priceTrade Entry Report & Community Consensus Stock Picks - baoquankhu1.vn

Jan 18, 2026

Jan 17, 2026

Trend Report: Will TNON benefit from seasonalityPortfolio Gains Summary & Stepwise Trade Execution Plans - baoquankhu1.vn

Jan 17, 2026

Dow Update: Can Iovance Biotherapeutics Inc deliver consistent EPS growthPortfolio Performance Report & Expert Curated Trade Setup Alerts - baoquankhu1.vn

Jan 17, 2026

Why Iovance Biotherapeutics Stock Got Mashed on Monday - MSN

Jan 17, 2026

Jan 16, 2026

Analyst Boosts Iovance’s Price Target Amid Positive Market Moves - timothysykes.com

Jan 16, 2026

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

Jan 16, 2026

Biotech Iovance offers 97,710 stock options to 17 new hires at $2.22 - Stock Titan

Jan 16, 2026

Iovance Biotherapeutics Stock Surges Amid Strategic Moves - StocksToTrade

Jan 16, 2026

Is Iovance Biotherapeutics (IOVA) A Potential Opportunity After Multi Year Share Price Slide - Sahm

Jan 16, 2026

Iovance Biotherapeutics (IOVA) Is Down 14.9% After Governance Scrutiny And Equity Raise Plan Is Revealed - Yahoo Finance

Jan 16, 2026

Jan 15, 2026

Iovance Biotherapeutics (IOVA) Valuation Check After Amtagvi Outlook Reaffirmation And Governance Concerns - Yahoo Finance

Jan 15, 2026